Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Roche files EMEA marketing authorization for Herceptin as breast cancer treatment
March 16th, 2006
Roche announced the submission of a marketing authorization application to the European Medicines Agency (EMEA) for Herceptin (trastuzumab) as adjuvant treatment for early-stage HER2-positive breast cancer. The application is based on data from the international (Herceptin Adjuvant (HERA) study, which showed that Herceptin following standard chemotherapy significantly reduces the risk of cancer coming back, by an outstanding 46%. HER2-positive breast cancer, which affects approximately 20 - 30% of women with breast cancer, demands special and immediate attention because HER2-positive tumors are fast growing. Results from four large trials, with...
Source: Women's Health Weekly (2006-03-16)
|
